Latuda, by contrast, is considered weight neutral. In clinical trials of lurasidone (Latuda's generic name), weight gain was less than a quarter of that gained by patients taking olanzapine (Zyprexa). The conclusion was that "Overall, the effects of lurasidone on increasing the risk of developing metabolic syndrome is minimal."
In May 2012, a pooled analysis of six studies found that while 12% of 371 patients had gained weight, 28.6% of patients had their weight status changed from overweight to normal weight. The study authors said the results showed that patients who started out overweight or obese were more likely to lose weight than those who were underweight or normal weight at the beginning.
This is not to say Latuda is a wonder drug for weight loss, but so far the indications are promising, especially since the overall side effect profile is basically the same as for other atypical antipsychotics.
More information: Latuda Drug Profile
Ehret, MJ, et al. Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia. Formulary. 1 Nov 2010.
Meyer, JM, et al. Lurasidone Not Associated With Weight Gain in Patients With Schizophrenia. May 2012.